|View printer-friendly version|
|February 09, 2006 1:30 p.m.|
|Teva Comments on Pfizer Press Release Regarding Azithromycin|
Jerusalem, Israel, February 9, 2006 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today commented on Pfizer's February 8th press release regarding azithromycin. Although Teva has not yet seen the Citizen Petition or the complaint relating to the infringement actions referenced in the press release, Teva believes that these allegations are baseless and without merit. Furthermore, the Company believes that Pfizer's efforts here are a thinly veiled attempt to discredit Teva and the entire generic drug industry, which have been providing affordable, safe pharmaceutical products to patients for decades.